Azione TKD TAKEDA PHARMACEUTICAL COMPANY LIMITED
Aggiungi a un elenco
Solo clienti o iscritti possono usare questa funzione
AccediRegistrati

Altre lingue Takeda Pharmaceutical Company Limited BOERSE MUENCHEN

Azioni

TKD

JP3463000004

Tempo reale BOERSE MUENCHEN
Altri mercati azionari
 08:00:04 25/06/2024 		Variaz. 5gg Var. 1 gen.
24,51 EUR +1,87% Grafico intraday di Takeda Pharmaceutical Company Limited -2,47% -7,07%
24/06 Hutchmed Cina nota che Takeda ha ottenuto l'approvazione dell'UE per Fruzaqla AN
24/06 Il trattamento per l'infezione da trapianto d'organo di Takeda approvato dalle autorità di regolamentazione giapponesi MT

Altre lingue

Ricerca
Vedi i risultati
Sblocca tutte le notizie su tutte le aziende: non perdere mai più un'opportunità di investimento redditizia!
Registrazione 100% gratuita
Hutchmed China notes Takeda obtains EU approval for Fruzaqla
Takeda's Organ Transplant Infection Treatment Approved by Japan Regulators
Hutchmed (China), Takeda Secure EU Approval for Colorectal Cancer Treatment
Takeda Announces Approval of LIVTENCITY® (maribavir) in Japan for Post-Transplant Cytomegalovirus (CMV) Infection/Disease That Is Refractory to Existing Anti-CMV Therapies
Takeda Announces Approval of LIVTENCITY® by the Japanese Ministry of Health, Labour and Welfare
Japanese Shares End Higher as BoJ Indicates Readiness for Policy Shifts
Takeda Receives European Commission Approval for Colorectal Cancer Treatment
Takeda Receives European Commission Approval for FRUZAQLA® (fruquintinib)
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda Presents Late-Breaking Data from Phase 2b Study of Mezagitamab, Demonstrating Potential to Transform Treatment of Primary Immune Thrombocytopenia
Takeda Secures European Commission's Approval for Colorectal Cancer Drug Fruzaqla
Takeda Pharmaceutical Gets European Commission Approval for Cancer Treatment
Takeda Receives Approval from European Commission for FRUZAQLA in Previously Treated Metastatic Colorectal Cancer
Takeda Receives Approval from European Commission for Fruquintinib in Previously Treated Metastatic Colorectal Cancer
Takeda's HyQvia® Approved as Replacement Therapy for Primary Humoral Immunodeficiency and Secondary Humoral Immunodeficiency in Pediatric Patients 2 years of Age and Older
Les sorcières épouvantent l'IA
Japanese Stocks End Little Changed After Three-Day Winning Streak on Inflation and Yen Woes
En Direct des Marchés : LVMH, Accor, Alstom, Atos, Casino, Plastivaloire, Boeing, Geberit...
Bolsa de Madrid: Las brujas aterrorizan a la IA
Takeda gives Sun Pharma, Cipla rights to commercialize gastro drug in India
Non ci sono risultati per questa ricerca
Tutte le notizie Raccomandazione analisti Eventi più importanti Insiders Resoconti Comunicati stampa Pubblicazioni ufficiali Altre lingue Idee di trading Articoli MarketScreener Analisi MarketScreener

Filtri

Cerca

Data di pubblicazione

Da

A

  1. Borsa valori
  2. Azioni
  3. Azione 4502
  4. Azione TKD
  5. Notizie Takeda Pharmaceutical Company Limited
  6. Altre lingue